Skip to main content

and
  1. Article

    Open Access

    Redefinition of dementia care in Italy in the era of amyloid-lowering agents for the treatment of Alzheimer’s disease: an expert opinion and practical guideline

    No disease-modifying therapies are currently available for Alzheimer’s disease (AD) in Europe. Current evidence from clinical trials testing anti-beta amyloid (Aβ) monoclonal antibodies (mAbs) in patients with...

    Massimo Filippi, Giordano Cecchetti, Annachiara Cagnin in Journal of Neurology (2023)

  2. Article

    Open Access

    Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington’s and Parkinson’s disease

    Proenkephalin (PENK) and prodynorphin (PDYN) are peptides mainly produced by the striatal medium spiny projection neurons (MSNs) under dopaminergic signaling. Therefore, they may represent candidate biomarkers...

    Peggy Barschke, Samir Abu-Rumeileh, M. H. D. Rami Al Shweiki in Journal of Neurology (2022)

  3. No Access

    Article

    The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI

    Measures to define treatment response, such as no evidence of disease activity (NEDA), are routinely used in multiple sclerosis (MS) clinical practice. Although spinal cord involvement is a frequent feature of...

    Elena Di Sabatino, Lorenzo Gaetani, Silvia Sperandei, Andrea Fiacca in Journal of Neurology (2022)

  4. No Access

    Article

    Changes of olfactory tract in Parkinson’s disease: a DTI tractography study

    Impaired olfactory function is one of the main features of Parkinson’s disease. However, how peripheral olfactory structures are involved remains unclear. Using diffusion tensor imaging fiber tracking, we inve...

    Pasquale Nigro, Andrea Chiappiniello, Simone Simoni in Neuroradiology (2021)

  5. No Access

    Article

    Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis

    Cognitive impairment (CI) is a disabling symptom of multiple sclerosis (MS). Axonal damage disrupts neural circuits and may play a role in determining CI, but its detection and monitoring are not routinely per...

    Lorenzo Gaetani, Nicola Salvadori, Viviana Lisetti, Paolo Eusebi in Journal of Neurology (2019)

  6. Article

    Open Access

    Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease

    Tau is an axonal microtubule-binding protein. Tau pathology in brain and increased tau concentration in the cerebrospinal fluid (CSF) are hallmarks of Alzheimer’s disease (AD). Most of tau in CSF is present as...

    Claudia Cicognola, Gunnar Brinkmalm, Jessica Wahlgren in Acta Neuropathologica (2019)

  7. No Access

    Article

    CSF Biomarkers for Early Diagnosis of Synucleinopathies: Focus on Idiopathic RBD

    Idiopathic REM sleep behavior disorder (iRBD) is one of the most significant prodromal manifestations of synucleinopathies. Different predictive biomarkers for iRBD conversion have been investigated, but scarc...

    Claudio Liguori, Federico Paolini Paoletti in Current Neurology and Neuroscience Reports (2019)

  8. No Access

    Article

    Selection of thrombogenetic antiphospholipid antibodies in cerebrovascular disease patients

    Background and Purpose: The association between anticardiolipin antibodies (aCL) and thrombosis is well recognized, but its role as an independent risk factor for stroke is not. The study's aim was to investigat...

    Valeria Caso, Lucilla Parnetti, Paolo Panarelli in Journal of Neurology (2003)

  9. No Access

    Article

    Clinical and genetic analysis of an Italian family with Machado-Joseph disease

    Paolo Forleo, Elena Cellini, Lucilla Parnetti, Donatella Murasecco in Journal of Neurology (2001)